Jury still out on Sarepta’s next generation
The group’s lead next-gen exon skipper beats a low bar set by Exondys, but adverse events loom large.
Adverum halt raises more gene therapy questions
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Epidermolysis bullosa gene therapies wait in the wings
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
Aldeyra eyes the future
A pivotal hit in allergic conjunctivitis could also bode well for upcoming readouts in the bigger indication of dry eye disease.
Astra and Sanofi’s RSV jab takes a step towards market
A pivotal win puts nirsevimab on track to be filed next year, but the reimbursement hurdle looms.
Bristol’s Tyk2 ticks the boxes
Bristol’s new oral psoriasis option looks much better than Otezla, but competing against injectables could be tricky.
Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
